Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Copper-Induced Expression of a Transmissible Lipoprotein Intramolecular Transacylase Alters Lipoprotein Acylation and the Toll-Like Receptor 2 Response to Listeria monocytogenes.

Armbruster KM, Komazin G, Meredith TC.

J Bacteriol. 2019 Jun 10;201(13). pii: e00195-19. doi: 10.1128/JB.00195-19. Print 2019 Jul 1.

PMID:
30988036
2.

Synthesis and antiviral activities of 3-deaza-3-fluoroaristeromycin and its 5' analogues.

Chen Q, Liu C, Komazin G, Bowlin TL, Schneller SW.

Bioorg Med Chem. 2014 Dec 15;22(24):6961-4. doi: 10.1016/j.bmc.2014.10.014. Epub 2014 Nov 6.

PMID:
25456389
3.

Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice.

Prichard MN, Quenelle DC, Bidanset DJ, Komazin G, Chou S, Drach JC, Kern ER.

Virol J. 2006 Mar 29;3:18.

5.

Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.

Evers DL, Komazin G, Ptak RG, Shin D, Emmer BT, Townsend LB, Drach JC.

Antimicrob Agents Chemother. 2004 Oct;48(10):3918-27.

6.
7.

Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs.

Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC.

Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):1725-7. No abstract available.

PMID:
14565505
8.

Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.

Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC.

J Virol. 2003 Nov;77(21):11499-506.

9.

Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus.

Evers DL, Komazin G, Shin D, Hwang DD, Townsend LB, Drach JC.

Antiviral Res. 2002 Oct;56(1):61-72.

PMID:
12323400

Supplemental Content

Loading ...
Support Center